Coleman R J, Lange K W, Quinn N P, Loper A E, Bondi J V, Hichens M, Stahl S M, Marsden C D
Institute of Neurology, London, U.K.
Mov Disord. 1989;4(2):129-38. doi: 10.1002/mds.870040204.
(+)-4-Propyl-9-hydroxynaphthoxazine (+PHNO) is a potent dopamine agonist that has been administered transdermally to four patients with Parkinson's disease and "on-off" fluctuations. Skin patches of increasing size were used to treat these patients, who also received infrequent doses of oral levodopa if required. The effect of +PHNO was measured as an increased duration of action of individual levodopa doses. The clinical effect measured in this way was directly proportional to the plasma concentrations of +PHNO achieved. The plasma concentrations of +PHNO began to rise 4-6 h after patch application and reached a steady state by 24 h. The final plasma concentration of +PHNO was proportional to the area of skin covered.
（+）-4-丙基-9-羟基萘并恶嗪（+PHNO）是一种强效多巴胺激动剂，已通过透皮给药用于4例患有帕金森病且有“开-关”波动的患者。使用尺寸不断增大的皮肤贴片来治疗这些患者，如有需要，他们还会偶尔服用口服左旋多巴。+PHNO的效果通过单个左旋多巴剂量作用持续时间的延长来衡量。以这种方式测得的临床效果与所达到的+PHNO血浆浓度直接成正比。+PHNO的血浆浓度在贴片应用后4 - 6小时开始上升，并在24小时达到稳态。+PHNO的最终血浆浓度与覆盖的皮肤面积成正比。
